Cargando…
Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19)
BACKGROUND: Cytokine release syndrome is a serious complication of the new coronavirus infection (COVID-19). The aim of the study was to assess effectiveness and safety of the IL-17 antagonist nekatimab for its treatment. METHODS: The retrospective study included COVID-19 patients with C-reactive pr...
Autores principales: | Maslennikov, Roman, Ivashkin, Vladimir, Vasilieva, Ekaterina, Chipurik, Maxim, Semikova, Polina, Semenets, Victoria, Russkova, Tatyana, Levshina, Anna, Grigoriadis, Diana, Magomedov, Shamil, Efremova, Irina, Dzhakhaya, Natiya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Libbey Eurotext
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491178/ https://www.ncbi.nlm.nih.gov/pubmed/34346869 http://dx.doi.org/10.1684/ecn.2021.0463 |
Ejemplares similares
-
Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19
por: Maslennikov, Roman, et al.
Publicado: (2021) -
Early viral versus late antibiotic-associated diarrhea in novel coronavirus infection
por: Maslennikov, Roman, et al.
Publicado: (2021) -
Epidemiology of small intestinal bacterial overgrowth
por: Efremova, Irina, et al.
Publicado: (2023) -
Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
por: Bryushkova, Ekaterina A., et al.
Publicado: (2022) -
A Metabolic Activity Recovery of the Intestinal Microbiota in the Patients with Bronchial Asthma
por: Ozimek, Mariusz, et al.
Publicado: (2022)